健康元：健康元药业集团股份有限公司2023年年度报告（英文版）

JoincarePharmaceuticalGroupAnnualReport2023 StockCode:600380StockShortName:健康元 JoincarePharmaceuticalGroupIndustryCo.,Ltd. 2023AnnualReport 1 ImportantNotice I.TheBoardofDirectors(the“Board”),theBoardofSupervisorsanddirectors,supervisorsandseniormanagementoftheCompanyherebywarrantthetruthfulness,accuracyandcompletenessofthecontentsofthisannualreport(the“Report”),andthattherearenofalserepresentations,misleadingstatementsormaterialomissionscontainedintheReport,andseverallyandjointlyacceptlegalresponsibility. II.AlldirectorsoftheCompanyattendedtheBoardmeeting. III.GrantThornton(SpecialGeneralPartnership)issuedastandardunqualifiedauditreportfortheCompany. IV.Mr.ZhuBaoguo(朱保国),theperson-in-chargeoftheCompany,andMr.QiuQingfeng(邱庆丰),theperson-in-chargeofaccountingworkandtheperson-in-chargeoftheaccountingdepartment(theheadoftheaccountingdepartment)declarethattheyherebywarrantthe truthfulness,accuracyandcompletenessofthefinancialstatementscontainedintheReport. V.ProfitdistributionplanorplanforconversionofcapitalreservetosharecapitalapprovedbytheBoardresolutionduringtheReportingPeriod BasedontheauditconductedbyGrantThornton(SpecialGeneralPartnership),in2023,theParentCompanygeneratednetprofitofRMB1,241,411,898.00,10%ofwhichwascontributedtothestatutorysurplusreserve,namelyRMB124,141,189.80,theremainderofwhich,togetherwithundistributedprofitsforthelastyearofRMB1,968,175,713.20andgainondisposalofotherequityinvestmentsofRMB1,245,892.23,subtractingcashdividendsforthelastyearofRMB336,792,056.76,istheprofitsavailablefordistributiontoshareholdersfortheyearofRMB2,749,900,256.87.TheCompanyplanstodistributecashdividendsforthefiscalyear2023,basedonthetotalnumberofsharesfordividenddistribution,whichisdefinedbythetotalsharesofCompanyontheequityregistrationdatedesignatedbytheannualprofitdistributionplan.TheCompanyplanstodistributecashdividendofRMB1.80(taxinclusive)forevery10sharesoftoallshareholdersoftheCompany,andtheremainingundistributedprofitswillbecarriedforwardtothefollowingyear. VI.Riskdeclarationfortheforward-lookingstatements √Applicable□N/A TheReportcontainsforward-lookingstatementswhichinvolvethefutureplans,developmentstrategies,etc.oftheCompany,yetdonotconstitutesubstantiveundertakingsoftheCompanytoinvestors.Investorsshouldexercisecautionpriortomakinginvestmentdecisions. VII.Whetherthereisnon-operatinguseoffundsbythecontrollingshareholderandtheirrelatedparties No VIII.Whetherthereisaviolationoftheprescribeddecision-makingprocedurestoprovideexternalguarantees No IX.Whethermorethanhalfofdirectorscannotwarrantthetruthfulness,accuracyandcompletenessoftheReportdisclosedbytheCompany No X.Significantriskwarnings ThereisnoexceptionallysignificantriskthatwillhaveamaterialimpactontheproductionandoperationoftheCompanyduringtheReportingPeriod.InthisReport,theCompanyhaselaboratedontherisksandcountermeasuresthattheCompanymayfaceinthecourseofproductionandoperation,includingindustrypolicyrisk,marketrisk,riskofsafetyandenvironmentalprotection,riskinpriceandsupplyofrawmaterialsandR&Drisk.Formoreinformation,pleasereferto“Potentialrisks”partinChapter3ManagementDiscussionandAnalysis. XI.Others □Applicable√N/A TableofContents ImportantNotice2 Chairman'sStatement5 FinancialHighlights9 Chapter1Definitions11 Chapter2CompanyProfileandMajorFinancialIndicators13 Chapter3ManagementDiscussionandAnalysis18 Chapter4CorporateGovernance78 Chapter5EnvironmentalandCorporateSocialResponsibility100 Chapter6MajorEvents128 Chapter7ChangesinEquityandShareholders146 Chapter8InformationonPreferredShares153 Chapter9InformationonBonds154 Chapter10FinancialStatements155 Listofdocumentsavailableforinspection TheFinancialStatementssignedandsealedbytheperson-in-chargeoftheCompany,theperson-in-chargeoftheCompany'saccountingworkandtheperson-in-chargeoftheaccountingdepartment(theheadoftheaccountingdepartment)Theoriginaldocumentoftheauditors’reportsealedbytheaccountingfirmandsignedandsealedbythecertifiedpublicaccountantsTheoriginalcopiesofalldocumentsandannouncementsoftheCompanywhichhavebeendisclosedtothepubliconthewebsitedesignatedbyCSRC(ChinaSecuritiesRegulatoryCommission)duringtheReportingPeriod Chairman'sStatement Dearshareholders, 2023markedthefirstyearoftheimplementationoftheguidingprinciplesofthe20thCPCNationalCongress.China’shealthundertakingsmadenewsignificantachievementsandtheconstructionofhealthyChinaaccelerated.Thisyear,thepharmaceuticalsindustryunderwentall-sector,full-chainandfull-coveragesystemgovernance,whileindustry-friendlypolicieswereintroducedfrequentlyamidstchallengesandopportunities.Drivenbypolicysupport,scientificandtechnologicalinnovation,andmarketdemand,thepharmaceuticalindustrysystemwitnessednotableoptimizationandupgrading,withinnovation-ledandhigh-qualitydevelopmentemergingastheprevailingtheme. Inretrospectof2023,Joincareadheredtoitsdual-drivestrategyofinnovativemedicinesandhigh-barriercomplexformulations,focusingonthehigh-qualitydevelopmentoftheprincipalpharmaceuticalbusiness.Overcomingchallenges,Joincarenotonlyachievedsubstantialachievement